|
Feb 12
|
Q4 2024 SAGE Therapeutics Inc Earnings Call
|
|
Feb 12
|
Biogen expects 2025 profit decline despite strong Q4
|
|
Feb 12
|
Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma
|
|
Feb 12
|
Biogen (BIIB) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
|
|
Feb 12
|
Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates
|
|
Jan 4
|
These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024
|
|
Jan 2
|
Piper Sandler downgrades Biogen, slashes PT by $177 amid transition challenges
|
|
Jan 1
|
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
|
|
Jan 1
|
The 5 worst performing stocks on the Nasdaq 100 in 2024
|
|
Dec 11
|
Biogen reinstated with a Neutral at BofA
|
|
Dec 10
|
Biogen Stock Declines 21.4% in 3 Months: How to Play the Stock
|
|
Dec 9
|
Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown
|
|
Dec 9
|
Biogen cut at Jefferies as '2025 has a tough setup'
|
|
Oct 10
|
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
|
|
Oct 10
|
Biogen scores breakthrough status for anti-rejection transplant medication
|
|
Oct 9
|
Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
|
|
Oct 8
|
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
|
|
Oct 2
|
Biogen Inc. (BIIB): Among the Best Bargain Stocks to Buy In October
|
|
Sep 27
|
SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324
|
|
Sep 26
|
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
|